Baric Transcribed Interview (Redacted) — page 15

DC.Scheduling@LexitasLegal.com old mice, and it was extremely effective. I think that data was immediately incorporated into the discussions, that I was not part of, but discussions at the Federal level, in terms of prioritizing which vaccines might go forward. So the reason, I think, that we were particularly so excited about that data is that most of the vaccines that I have tested against coronaviruses, epidemic or pandemic, not pandemic, epidemic coronaviruses like the original SARS 2003 strain, or the MERS strain, worked effectively in young animals. But when you took them into aged animals, where the vaccines are less affected by about tenfold, the vaccines would fail. And the beauty about the VRC mRNA vaccine was that the neutralizing titers in the immune responses were as effective in the old animals as the young animals, so they were fully protected. And that was very impressive. MS. SALAZAR: And so the VRC Moderna vaccine. DR. BARIC: Yeah. Moderna certainly was engaged. Whether they actually manufactured the vaccine that was put in the animals or not, or whether NIH made that vaccine and put it in, I don't know. MS. SALAZAR: And your vaccine, what was it called? DR. BARIC: Oh, the Moderna vaccine? MS. SALAZAR: No, no, no. Yours, the one that you had